Skip to main content

Investor

By Emily Olsen | 11:07 am | December 30, 2022
Elena Viboch, partner at General Catalyst, discusses her predictions for biotech and health tech investing and how startups can grow in a more constrained economic environment.
By Emily Olsen | 11:50 am | December 29, 2022
Although investment slowed for startups, leaders noted several big deals in digital health, particularly among retail players.
By Jessica Hagen and Emily Olsen | 01:15 pm | December 28, 2022
Drug development platform Quris raised another $9 million, and PharmStars is accepting applications for its accelerator cohort focused on women's health and health equity.
By Jessica Hagen | 12:17 pm | December 28, 2022
Execs said investors will focus on companies with evidence of market fit, established business models and those achieving measurable health outcomes.   
By Jessica Hagen | 11:25 am | December 27, 2022
The year was plagued by layoffs, slowing investments and an increased need for companies to prove their market value.
By Emily Olsen | 07:20 pm | December 22, 2022
The U.S. International Trade Commission determined Apple Watches with ECG functionality violate AliveCor patents, but an import ban is on hold until appeals wrap up in a case before the U.S. Patent and Trademark Office's Patent Trial and Appeal Board.
By Emily Olsen | 01:17 pm | December 22, 2022
Nomi Health appointed its first chief product officer, and Hims & Hers announced that its first chief medical officer has returned to the role.
By Emily Olsen | 11:36 am | December 22, 2022
Aegis Ventures' John Beadle discusses partnerships between venture capital firms and health systems, the move from direct-to-consumer to business-to-business models and what digital health investment could look like next year.
By Jessica Hagen | 02:16 pm | December 21, 2022
The execs spotlight the year's rise of home healthcare, drop in digital health investment and expanded use of AI, in addition to the value of virtual care.
By Jessica Hagen | 01:34 pm | December 20, 2022
The investment will support Nectar's growth nationwide, fund clinical trials and help the company open a physical location.